Nyxoah SA (FRA:5YI)
Germany · Delayed Price · Currency is EUR | Market Cap | 78.06M -58.6% |
| Revenue (ttm) | 21.66M +339.1% |
| Net Income | -96.00M |
| EPS | -2.16 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,000 |
| Open | 0.7140 |
| Previous Close | 0.8310 |
| Day's Range | 0.5930 - 0.7140 |
| 52-Week Range | 0.5930 - 5.2000 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Nyxoah
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium. [Read more]
Financial Performance
In 2025, Nyxoah's revenue was 10.02 million, an increase of 121.63% compared to the previous year's 4.52 million. Losses were -90.09 million, 52.1% more than in 2024.
Financial StatementsNews
Nyxoah reports preliminary Q3 revenue EUR 9.2M, consensus EUR 9.93M
“We delivered 29% sequential revenue growth in the U.S. in the third quarter, and our International business performed in line with our expectations. While we are disappointed to adjust our…
Nyxoah cuts FY26 revenue view to EUR 33M-EUR 35M from EUR 36M-EUR 40M
Consensus EUR 37.27M. The company said, “The Company now expects global net revenue for the full year 2026 to be in the range of EUR 33 million to EUR 35…
Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026
REGULATED INFORMATION INSIDE INFORMATION Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026 U.S. net revenue grows 29% sequentially, driving third...
Nyxoah presents complete ACCCESS U.S. study data, submits PMA supplement to FDA
Nyxoah (NYXH) announced that the complete 12-month results of the ACCCESS U.S. pivotal study were presented at the International Surgical Sleep Society, or ISSS, annual meeting, taking place October 1...
Nyxoah names Liam Kelly as CEO, succeeding Olivier Taelman
Nyxoah (NYXH) announced the appointment of Liam Kelly as CEO, effective October 1, succeeding Olivier Taelman. The appointment reflects Nyxoah’s continued evolution into a U.S.-focused commercial orga...
Nyxoah Appoints Liam Kelly as Chief Executive Officer
REGULATED INFORMATION INSIDE INFORMATION Nyxoah Appoints Liam Kelly as Chief Executive Officer Further strengthening the Company's strategic U.S. presence and focus Mont-Saint-Guibert, Belgium – Septe...
Nyxoah announces CFO transition
Nyxoah (NYXH) SA announced that John Landry, CFO, will step down from his role effective October 2 to pursue another professional opportunity. Loic Moreau, the company’s president international and fo...
Nyxoah Announces Chief Financial Officer Transition
REGULATED INFORMATION INSIDE INFORMATION Nyxoah Announces Chief Financial Officer Transition Loïc Moreau, Nyxoah's President International and former CFO, to serve as interim CFO Company reaffirms ful...
Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System
Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio ® System
Nyxoah announces ACCESS study meets primary safety, efficacy endpoints
Nyxoah (NYXH) announced that the ACCCESS U.S. pivotal study achieved statistically significant outcomes on its co-primary efficacy endpoints of 12-month AHI responder rate, per the Sher criteria, and ...
Nyxoah Slides: Investor presentation
Nyxoah has posted slides in relation to its latest quarterly earnings report, which was published on September 1, 2026.
Nyxoah price target lowered to $6 from $11 at Cantor Fitzgerald
Cantor Fitzgerald analyst Sarah James lowered the firm’s price target on Nyxoah (NYXH) to $6 from $11 and keeps an Overweight rating on the shares. Nyxoah expanded U.S. commercialization with…
Nyxoah price target lowered to $2.31 from $2.86 at Baird
Baird lowered the firm’s price target on Nyxoah (NYXH) to $2.31 from $2.86 and keeps a Neutral rating on the shares. The firm updated its model following Q2 results. Published…
Nyxoah price target lowered to $6 from $7 at Piper Sandler
Piper Sandler analyst Adam Maeder lowered the firm’s price target on Nyxoah (NYXH) to $6 from $7 and keeps an Overweight rating on the shares following quarterly results. Big picture,…
Nyxoah price target lowered to $4 from $13 at Oppenheimer
Oppenheimer lowered the firm’s price target on Nyxoah (NYXH) to $4 from $13 and keeps an Outperform rating on the shares. The firm notes Nyxoah reported Q2 net revenue of…
Nyxoah Q2 Earnings Call Highlights
Nyxoah NASDAQ: NYXH reported second-quarter worldwide net revenue of €7.7 million, up 21% sequentially from the first quarter, as its U.S. commercial launch continued to expand. U.S. net revenue reach...
Nyxoah Earnings Call Transcript: Q2 2026
Q2 2026 saw 21% sequential revenue growth, driven by U.S. and international expansion, with gross margin rising to 60%. The company doubled its active U.S. accounts, secured $110 million in financing, and maintained strong guidance for 2026, supported by robust reimbursement and market adoption.
Nyxoah Earnings release: Q2 2026
Nyxoah released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results
REGULATED INFORMATION Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results U.S. commercial execution driving continued launch momentum resulting in 22% sequential U.S. rev...
Nyxoah to Release Second Quarter 2026 Financial Results on August 5, 2026
Nyxoah to Release Second Quarter 2026 Financial Results on August 5, 2026 Mont-Saint-Guibert, Belgium – July 27, 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or...
Nyxoah Touts Genio U.S. Launch Traction, Reimbursement Stability at Investor Day
Nyxoah NASDAQ: NYXH used its investor day presentation to outline early U.S. launch progress for its Genio hypoglossal nerve stimulation system, address reimbursement questions and describe its path t...
Nyxoah price target lowered to $2.85 from $4 at Baird
Baird lowered the firm’s price target on Nyxoah (NYXH) to $2.85 from $4 and keeps a Neutral rating on the shares. The firm updated its model following its investor day…
Nyxoah Transcript: CMD 2026
Genio’s differentiated bilateral stimulation and patient-centric design are driving rapid adoption in the U.S., supported by robust financial growth, stable reimbursement, and a clear path to profitability. Strategic focus on innovation, market expansion, and collaboration with physician societies positions the company for sustainable leadership in the underpenetrated OSA market.
Nyxoah sees Q2 revenue EUR 7.7M
“We closed Q2 with clear U.S. momentum: the scaling of our U.S. sales force allowed us to double the number of active accounts to 180 high-volume HGNS accounts and deliver…
Nyxoah backs FY26 revenue view EUR 36M-EUR 40M
The company said, “The Company continues to expect global net revenue for the full year 2026 to be in the range of EUR 36 million to EUR 40 million.” Published…